Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
- Associated Therapies
- -
A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2011-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 111
- Registration Number
- NCT00454246
Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)
Phase 2
- Conditions
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2007-05-17
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 99
- Registration Number
- NCT00443339
- Locations
- 🇫🇷
CHU d'Avignon, Avignon, France
🇫🇷Hopital Percy, Clamart, France
🇫🇷CHU de Caen, Caen, France
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 228
- Registration Number
- NCT00442702
Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 114
- Registration Number
- NCT00436995
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 116
- Registration Number
- NCT00436748
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 239
- Registration Number
- NCT00416624
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Darbepoetin Alfa With or Without Intravenous (IV) Iron
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 243
- Registration Number
- NCT00401544
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 490
- Registration Number
- NCT00394953
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2013-07-19
- Target Recruit Count
- 235
- Registration Number
- NCT00386152
Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer
Phase 2
Terminated
- Conditions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 140
- Registration Number
- NCT00381836
- Locations
- 🇩🇰
Department of Urology, Aarhus University Hospital, Aarhus, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath